55289-05-9

Basic information

• Product Name: METHYL 3-HYDROXY-2-METHYLBENZOATE
• Synonyms: METHYL 3-HYDROXY-2-METHYLBENZOATE;Methyl 2-methyl-3-hydroxybenzoate;3-Hydroxy-2-methylbenzoic acid methyl ester;Benzoic acid, 3-hydroxy-2-methyl-, methyl ester
• CAS NO: 55289-05-9
• Molecular Formula: C₉H₁₀O₃
• Molecular Weight: 166.1739
• EINECS: 200-258-5
• Product Categories: Aromatic Esters
• Mol File: 55289-05-9.mol

Chemical Properties

• Melting Point: 66-67 °C(Solv: hexane (110-54-3))
• Boiling Point: 282.2±20.0 °C(Predicted)
• Appearance: /
• Density: 1.169±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.50±0.10(Predicted)
• CAS DataBase Reference: METHYL 3-HYDROXY-2-METHYLBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-HYDROXY-2-METHYLBENZOATE(55289-05-9)
• EPA Substance Registry System: METHYL 3-HYDROXY-2-METHYLBENZOATE(55289-05-9)

Safety Data

• Hazardous Substances Data: 55289-05-9(Hazardous Substances Data)

Usage

Uses

Used in Food and Beverage Industry:
METHYL 3-HYDROXY-2-METHYLBENZOATE is used as a flavoring agent for its ability to impart a sweet, fruity taste and aroma to food and beverages, enhancing the overall sensory experience for consumers.
Used in Pharmaceutical Industry:
METHYL 3-HYDROXY-2-METHYLBENZOATE is used in the synthesis of various pharmaceuticals, contributing to the development of new medications and improving the efficacy of existing ones.
Used in Cosmetics and Personal Care Products:
METHYL 3-HYDROXY-2-METHYLBENZOATE is used as a fragrance ingredient in cosmetics and personal care products, adding a pleasant scent and enhancing the appeal of these products to consumers.
It is important to handle METHYL 3-HYDROXY-2-METHYLBENZOATE with care, as it may cause irritation to the skin, eyes, and respiratory system if not properly managed.

Upstream product

• 67-56-1 methanol 
• 603-80-5 3-hydroxy 2-methylbenzoic acid 
• 18583-89-6 methyl 3-amino-2-methylbenzoate 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 52130-17-3 3-amino-2-methylbenzoic acid 
• 3260-87-5 3-chloro-o-cresol 
• 55289-04-8 3-hydroxy-2-methylbenzonitrile 
• 75-36-5 acetyl chloride 
• 144-55-8 sodium hydrogencarbonate 
• 1120-73-6 2-methyl-2-cyclopenten-1-one 
• 95-47-6 o-xylene 
• 83-41-0 2,3-dimethylnitrobenzene 

Downstream Products

• 104216-90-2 3-ethoxy-2-methyl-benzoic acid methyl ester 
• 42981-93-1 3-methoxy-2-methylbenzoic acid methyl ester 
• 467252-04-6 methyl 3-isobutoxy-2-methylbenzoate 
• 55289-16-2 methyl 6-bromo-3-methoxy-2-methylbenzoate 
• 55289-17-3 6-bromo-3-methoxy-2-methylbenzoic acid 
• 55289-18-4 methyl 6-cyano-3-methoxy-2-methylbenzoate 
• 55289-21-9 4-methoxy-3-methyl-phthalic acid 
• 134154-59-9 methyl 2-methyl-3-(naphth-2-ylmethoxy)benzoate 
• 24487-91-0 3-methoxy-2-methylbenzoyl chloride 
• 55289-06-0 3-methoxy-2-methylbenzoic acid 
• 1149388-20-4 4-bromo-3-methoxy-2-methylbenzoic acid methyl ester 
• 1033809-12-9 methyl 3-(2-chloro-4-nitrophenoxy)-2-methylbenzoate 
• 1149387-99-4 methyl 3-(allyloxy)-2-methylbenzoate 
• 1149388-19-1 methyl 4-bromo-3-hydroxy-2-methylbenzoate 

Relevant articles and documents

Synthesis process 2 - methyl -3 - methoxybenzoic acid

The invention discloses a synthesis process of 2 - methyl -3 - methoxybenzoic acid, which comprises the following steps: (1) reducing hydrogenation reaction: taking 2 - methyl -3 - nitrobenzoic acid or 2 - methyl -3 - nitrobenzoate as raw materials and methanol as a solvent. The hydrogen is a hydrogen source, and palladium carbon or platinum carbon is used as a catalyst to prepare 3 - amino -2 - methyl benzoic acid or 3 - amino -2 - methyl benzoic acid methyl ester by hydrogenation reduction. (2) Diazotization and hydrolysis and esterification one-pot reaction: preparing and hydroxyl 3 - methyl benzoic acid methyl ester by carrying out diazotization and hydrolysis -2 - esterification reaction under the action of a reducing product as a raw material and methanol as a solvent and a diazotization reagent. (3) Methylation reaction: methyl benzoate serving 3 - hydroxyl -2 - is used as a raw material, dimethyl sulfate is used as a methylation reagent, and methyl benzoate is produced 3 - methoxy -2 - methyl benzoate in the presence of a base. (4) Hydrolysis Reaction: methyl 3 - methoxy -2 - methyl benzoate and base. Water is mixed, heated and hydrolyzed, the reaction is complete, the product precipitated by acid conditioning PH through 1-3, filtered, and dried to obtain 3 - methoxy -2 -methylbenzoic acid.

Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands

Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin ligase have emerged as a novel paradigm in drug development. Herein we found that linker attachment points of CRBN ligands highly affect their aqueous stability and neosubstrate degradation features. This work provides a blueprint for the assembly of future heterodimeric CRBN-based degraders with tailored properties.

BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION

The disclosure relates to new compounds, including bifunctional compounds, to be used as modulators of ubiquitination for targeted protein degradation.

Co-production process of methyl 3-hydroxy-2-methyl benzoate and methyl 3-methoxy-2-methyl benzoate

The invention discloses a co-production process of 3-hydroxy-2-methyl benzoate and 3-methoxy-2-methyl benzoate, which comprises the following steps: (1) reduction hydrogenation reaction: by taking 2-methyl-3-nitrobenzoic acid or methyl 2-methyl-3-nitroben

DEGRADERS OF WEE1 KINASE

Disclosed are bifunctional compounds (degraders) that target Wee1 tyrosine kinase for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

ROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF

The present disclosure relates to compounds of the general formula (I): wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the mean survival of MM patients has more than doubled in recent years, most patients will eventually relapse. To address this need, we explored the potential of novel cereblon E3 ligase modulators (CELMoDs) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We found that optimization beyond potency of degradation, including degradation efficiency and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both phenotypic and protein degradation data, we describe a series of CELMoDs for the treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader and the first CELMoD to enter clinical development that was specifically designed for efficient and rapid protein degradation kinetics.

ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE

Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof,

PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME

Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, t

SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME

Provided herein are formulations, processes, solid forms and methods of use relating to salts of and solid forms comprising free base or salts of (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluoroben